August 6, 2021
Nephros Announces Results for Quarter Ended June 30, 2021
Second Quarter Net Revenue of $2.3 Million; 44% Year-Over-Year Increase; Strategic Acquisition of GenArraytion, Inc.; HDF Product Submitted to FDA…
Pharmaceuticals, Biotechnology and Life Sciences
Second Quarter Net Revenue of $2.3 Million; 44% Year-Over-Year Increase; Strategic Acquisition of GenArraytion, Inc.; HDF Product Submitted to FDA…
– Approximately $7 Million in International Sales of Oral TPOXX® in the Second Quarter – – Authorization of Additional $50…
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company…
Collaboration will initially explore the therapeutic potential of a combination of Imugene’s CF33-CD19 oncolytic virus (onCARlytics) and Celularity’s CD19 targeting…
MELBOURNE, Australia, Aug. 04, 2021 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces today that the…
LEXINGTON, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens,…
Las Vegas, NV, Aug. 04, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Sky Century Investment, Inc. (OTC Markets: SKYI), a…
Announced positive results of the Saturn-1 pivotal trial evaluating TP-03 for the treatment of Demodex blepharitis; results presented at the…
Special shareholder meeting to approve, among other items, the proposed business combination with Humacyte, Inc. to be held August 24,…
ROCKVILLE, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company…